为什么阿杜卡努单抗每位患者定价56000美元？药物定价改革的经验教训。 - Suppr

Suppr

超能文献

Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.

作者信息

Robinson James C

机构信息

From the University of California, Berkeley, School of Public Health, Berkeley.

出版信息

N Engl J Med. 2021 Nov 25;385(22):2017-2019. doi: 10.1056/NEJMp2113679. Epub 2021 Nov 20.

DOI:10.1056/NEJMp2113679

PMID:34797614

Abstract

摘要

相似文献

Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.

N Engl J Med. 2021 Nov 25;385(22):2017-2019. doi: 10.1056/NEJMp2113679. Epub 2021 Nov 20.

Medicare Coverage of Aducanumab - Implications for State Budgets.

N Engl J Med. 2021 Nov 25;385(22):2019-2021. doi: 10.1056/NEJMp2115297. Epub 2021 Nov 20.

Using Medicare Prices - Toward Equity and Affordability in the ACA Marketplace.

N Engl J Med. 2017 Dec 14;377(24):2309-2311. doi: 10.1056/NEJMp1710020. Epub 2017 Oct 18.

Healthcare 'reform': deep cuts likely for Medicare providers.

Geriatrics. 1994 Sep;49(9):54-6.

Medicare and drug pricing.

N Engl J Med. 2003 Apr 17;348(16):1590-7. doi: 10.1056/NEJMhpr035135.

US health reform: a mixed bag for insurers and drug companies.

Lancet Oncol. 2010 May;11(5):417-8. doi: 10.1016/s1470-2045(10)70083-8.

Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.

Ann Neurol. 2021 Sep;90(3):331-333. doi: 10.1002/ana.26167. Epub 2021 Aug 10.

Healthcare Reform: State Specific Responses.

Issue Brief Health Policy Track Serv. 2016 Dec 27;2016:1-35.

Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?

JAMA Intern Med. 2021 Oct 1;181(10):1278-1280. doi: 10.1001/jamainternmed.2021.4610.

Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?

JAMA. 2021 Aug 3;326(5):383-384. doi: 10.1001/jama.2021.11768.

引用本文的文献

The Potential of a Stratified Approach to Drug Repurposing in Alzheimer's Disease.

Biomolecules. 2023 Dec 21;14(1):11. doi: 10.3390/biom14010011.

Deep learning for risk-based stratification of cognitively impaired individuals.

iScience. 2023 Aug 2;26(9):107522. doi: 10.1016/j.isci.2023.107522. eCollection 2023 Sep 15.

Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease.

Brain Commun. 2023 Jun 2;5(3):fcad175. doi: 10.1093/braincomms/fcad175. eCollection 2023.

Payer-negotiated pricing of the hypoglossal nerve stimulator.

J Clin Sleep Med. 2022 Sep 1;18(9):2333-2334. doi: 10.5664/jcsm.10142.

Expedited regulatory product approval in the time of COVID-19.

Ocul Surf. 2022 Oct;26:345-348. doi: 10.1016/j.jtos.2022.05.007. Epub 2022 May 28.

A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

Int J Health Serv. 2022 Jul;52(3):363-371. doi: 10.1177/00207314221100647. Epub 2022 May 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.

N Engl J Med. 2021 Nov 25;385(22):2017-2019. doi: 10.1056/NEJMp2113679. Epub 2021 Nov 20.

Medicare Coverage of Aducanumab - Implications for State Budgets.

N Engl J Med. 2021 Nov 25;385(22):2019-2021. doi: 10.1056/NEJMp2115297. Epub 2021 Nov 20.

Using Medicare Prices - Toward Equity and Affordability in the ACA Marketplace.

N Engl J Med. 2017 Dec 14;377(24):2309-2311. doi: 10.1056/NEJMp1710020. Epub 2017 Oct 18.

Healthcare 'reform': deep cuts likely for Medicare providers.

Geriatrics. 1994 Sep;49(9):54-6.

Medicare and drug pricing.

N Engl J Med. 2003 Apr 17;348(16):1590-7. doi: 10.1056/NEJMhpr035135.

US health reform: a mixed bag for insurers and drug companies.

Lancet Oncol. 2010 May;11(5):417-8. doi: 10.1016/s1470-2045(10)70083-8.

Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.

Ann Neurol. 2021 Sep;90(3):331-333. doi: 10.1002/ana.26167. Epub 2021 Aug 10.

Healthcare Reform: State Specific Responses.

Issue Brief Health Policy Track Serv. 2016 Dec 27;2016:1-35.

Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?

JAMA Intern Med. 2021 Oct 1;181(10):1278-1280. doi: 10.1001/jamainternmed.2021.4610.

Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?

JAMA. 2021 Aug 3;326(5):383-384. doi: 10.1001/jama.2021.11768.

引用本文的文献

The Potential of a Stratified Approach to Drug Repurposing in Alzheimer's Disease.

Biomolecules. 2023 Dec 21;14(1):11. doi: 10.3390/biom14010011.

Deep learning for risk-based stratification of cognitively impaired individuals.

iScience. 2023 Aug 2;26(9):107522. doi: 10.1016/j.isci.2023.107522. eCollection 2023 Sep 15.

Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease.

Brain Commun. 2023 Jun 2;5(3):fcad175. doi: 10.1093/braincomms/fcad175. eCollection 2023.

Payer-negotiated pricing of the hypoglossal nerve stimulator.

J Clin Sleep Med. 2022 Sep 1;18(9):2333-2334. doi: 10.5664/jcsm.10142.

Expedited regulatory product approval in the time of COVID-19.

Ocul Surf. 2022 Oct;26:345-348. doi: 10.1016/j.jtos.2022.05.007. Epub 2022 May 28.

A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

Int J Health Serv. 2022 Jul;52(3):363-371. doi: 10.1177/00207314221100647. Epub 2022 May 12.